New developments in lung cancer diagnosis and pathological patient management strategies

摘要

During the last decade we have seen many changes in the field of Lung Pathology, and had to keep with the immense progress: new therapy options for lung cancer patients have changed our practice and required to learn from disciplines such as genetics and immunology. Numerous clinical studies are on the way, testing new drugs to interfere with the biology of lung cancer, and individualized therapy is no longer a vision, but daily reality. For oncologists it is even sometimes hard to recruit a sufficient number of lung cancer patients for the clinical trials. Pathologists have to test and evaluate the targets in a given cancer specimen to provide the information for the correct treatment—never before pathologists were such an important part in the clinical management team as now.